Cours actuels de Turnstone Biologics Corp. - Common Stock

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
NASDAQ	TSBX	USD	09.06.2025 19:58	0,37 USD	0,36 USD +1,74 %

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
4,87 %	17,68 %	2,08 %	-2,65 %	-26,25 %	-86,86 %	-96,65 %

Company Profile for Turnstone Biologics Corp. - Common Stock Share

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Company Data

Name Turnstone Biologics Corp. - Common Stock

Company Turnstone Biologics Corp.

Symbol TSBX

Website https://turnstonebio.com

Primary Exchange

NASDAQ

ISIN US90042W1009

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Dr. Sammy J. Farah M.B.A., Ph.D.

Country United States of America

Currency USD

Employees 0,0 T

Address 9310 Athena Circle, 92037 LA Jolla

IPO Date 2023-07-21

Ticker Symbols

Name	Symbol
NASDAQ	TSBX

More Shares

Investors who Turnstone Biologics Corp. - Common Stock hold also have the following shares in their portfolio:

DANONE SA Share

Direxion Daily Cloud Computing Bull 2X Shares ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog